Human Apolipoprotein A1 ELISA Kit | APO-A1 elisa kit

Human Apolipoprotein A1 (APO-A1) ELISA Kit

Cat. Num. AAA285069

• Gene Names: APOA1; apo(a)
• Reactivity: Human
• Synonyms: Apolipoprotein A1; Human Apolipoprotein A1 (APO-A1) ELISA Kit; Apo-A1; ApoA-1 Milano; ProapoA-I; Proapolipoprotein A-I; Truncated apolipoprotein A-I; APO-A1 elisa kit

• Reactivity: Human
• Specificity: This assay has high sensitivity and excellent specificity for detection of Human APOA1. No significant cross-reactivity or interference between Human APOA1 and analogues was observed.
• Sequence Length: 67

• Samples: Serum, Plasma, Other biological fluids
• Assay Type: Sandwich
• Sample Volume: 1-200 uL
• Precision: Intra-assay Precision (Precision within an assay); Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.; Inter-assay Precision (Precision between assays); Three samples of known concentration were tested in forty separate assays to assess inter-assay precision.; CV (%) = SD/meanX100; Intra-Assay: CV; Inter-Assay: CV
• Detection Wavelength: 450 nm
• Preparation and Storage: Store at 2-8 degree C.

Related Product Information for APO-A1 elisa kit

Apolipoprotein A-I the major protein component of high density lipoprotein (HDL) in plasma. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterolacyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters.
ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis.ApoA-1 Milano is a naturally occurring mutant of ApoA-I, found in a family descended from a single couple of the 18th century.


Principle of the Assay: This assay employs a two-site sandwich ELISA to quantitate APOA1 in samples. An antibody specific for APOA1 has been pre-coated onto a microplate. Standards and samples are pipetted into the wells and anyAPOA1 present is bound by the immobilized antibody. After removing any unbound substances, a biotin-conjugated antibody specific for APOA1 is added to the wells. After washing, Streptavidin conjugated Horseradish Peroxidase (HRP) is added to the wells. Following a wash to remove any unbound avidin-enzyme reagent, a substrate solution is added to the wells and color develops in proportion to the amount of APOA1 bound in the initial step. The color development is stopped and the intensity of the color is measured.

NCBI and Uniprot Product Information

• NCBI GI #: 4557321
• NCBI GeneID: 335
• NCBI Accession #: NP_000030.1
• NCBI GenBank Nucleotide #: NM_000039.2
• UniProt Accession #: P02647; Q6LDN9; Q6Q785; Q9UCS8; Q9UCT8; A8K866
• Molecular Weight: 30,778 Da
• NCBI Official Full Name: apolipoprotein A-I isoform 1 preproprotein
• NCBI Official Synonym Full Names: apolipoprotein A1
• NCBI Official Symbol: APOA1
• NCBI Official Synonym Symbols: apo(a)
• NCBI Protein Information: apolipoprotein A-I
• UniProt Protein Name: Apolipoprotein A-I
• UniProt Gene Name: APOA1
• UniProt Synonym Gene Names: Apo-AI; ApoA-I; ProapoA-I

NCBI Description

This gene encodes apolipoprotein A-I, which is the major protein component of high density lipoprotein (HDL) in plasma. The encoded preproprotein is proteolytically processed to generate the mature protein, which promotes cholesterol efflux from tissues to the liver for excretion, and is a cofactor for lecithin cholesterolacyltransferase (LCAT), an enzyme responsible for the formation of most plasma cholesteryl esters. This gene is closely linked with two other apolipoprotein genes on chromosome 11. Defects in this gene are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. Alternative splicing results in multiple transcript variants, at least one of which encodes a preproprotein. [provided by RefSeq, Dec 2015]

Uniprot Description

APOA1: Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. Interacts with APOA1BP and CLU. Component of a sperm activating protein complex (SPAP), consisting of APOA1, an immunoglobulin heavy chain, an immunoglobulin light chain and albumin. Interacts with NDRG1. Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. The oxidized form at Met-110 and Met-136 is increased in individuals with increased risk for coronary artery disease, such as in carrier of the eNOSa/b genotype and exposure to cigarette smoking. It is also present in increased levels in aortic lesions relative to native ApoA-I and increased levels are seen with increasing severity of disease. Belongs to the apolipoprotein A1/A4/E family.

Protein type: Cell development/differentiation; Endoplasmic reticulum; Lipid-binding; Motility/polarity/chemotaxis; Secreted; Secreted, signal peptide; Vesicle

Chromosomal Location of Human Ortholog: 11q23.3

Cellular Component: cell surface; chylomicron; cytoplasmic vesicle; cytosol; early endosome; endocytic vesicle; endoplasmic reticulum lumen; extracellular matrix; extracellular region; extracellular space; nucleus; plasma membrane

Molecular Function: amyloid-beta binding; apolipoprotein A-I receptor binding; apolipoprotein receptor binding; chemorepellent activity; cholesterol binding; cholesterol transporter activity; enzyme binding; heat shock protein binding; high-density lipoprotein particle binding; identical protein binding; lipase inhibitor activity; phosphatidylcholine binding; phospholipid binding; phospholipid transporter activity; protein binding

Biological Process: adrenal gland development; axon regeneration in the peripheral nervous system; blood vessel endothelial cell migration; cellular protein metabolic process; cholesterol biosynthetic process; cholesterol efflux; cholesterol homeostasis; cholesterol metabolic process; cholesterol transport; endothelial cell proliferation; G-protein coupled receptor signaling pathway; glucocorticoid metabolic process; integrin-mediated signaling pathway; lipid storage; lipoprotein biosynthetic process; lipoprotein metabolic process; negative chemotaxis; negative regulation of cytokine secretion involved in immune response; negative regulation of heterotypic cell-cell adhesion; negative regulation of inflammatory response; negative regulation of interleukin-1 beta secretion; negative regulation of lipase activity; neuron projection regeneration; organ regeneration; peptidyl-methionine modification; phosphatidylcholine biosynthetic process; phospholipid efflux; phospholipid homeostasis; platelet degranulation; positive regulation of fatty acid biosynthetic process; positive regulation of hydrolase activity; positive regulation of lipoprotein lipase activity; positive regulation of Rho protein signal transduction; positive regulation of stress fiber formation; post-translational protein modification; protein oxidation; protein stabilization; receptor-mediated endocytosis; regulation of Cdc42 protein signal transduction; regulation of intestinal cholesterol absorption; regulation of lipid metabolic process; regulation of protein amino acid phosphorylation; response to drug; response to estrogen; response to nutrient; retinoid metabolic process; reverse cholesterol transport; transforming growth factor beta receptor signaling pathway; transmembrane transport; triglyceride catabolic process; vitamin transport

Disease: Amyloidosis, Familial Visceral; Hypoalphalipoproteinemia, Primary